,i #aaith ,,congress #ast ,session ,h4 ,r4 #ecdc ,,in ,,the ,,house ,,of ,,representatives ,september #ae1 #bjbe,mr4 ,moore of ,utah 7for himself1 ,ms4 ,del,bene1 ,mr4 ,yakym1 ,ms4 ,sewell1 ,mr4 ,bilirakis1 and ,mrs4 ,trahan7 introduced the following bill2 which was referred to the ,committee on ,ways and ,means1 and in addition to the ,committee on ,energy and ,commerce1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xviii of the ,social ,security ,act to ensure prompt coverage of breakthrough devices under the ,medicare program4 #a4 ,short title ,this ,act may be cited as the ,ensuring ,patient ,access to ,critical ,breakthrough ,products ,act4 #b4 ,ensuring prompt coverage of breakthrough devices under the ,medicare program 7a7 ,ensuring coverage through a transitional coverage period 7#a7 ,in general ,section #ahfb7;a77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciey7a77#a77 is amended-- 7,a7 in subparagraph 7,o71 by striking and at the end2 7,b7 in subparagraph 7,p71 by adding and at the end2 and 7,c7 by inserting after subparagraph 7,p7 the following new subparagraph3 7,q7 in the case of a breakthrough device 7as defined in section #ahfa7nnn77 furnished during the transitional coverage period 7as so defined7 with respect to such device1 which is not furnished for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member in accordance with the ,food and ,drug ,administration-approved labeling for such device and for the indication for which such device was provided priority review under section #eae;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 or that the ,secretary finds1 based on a review of clinical data1 presents an undue risk of harm that outweighs the potential clinical benefits for individuals entitled to benefits under part ,a or enrolled under part ,b2 4 7#b7 ,definitions ,section #ahfa of the ,social ,security ,act 7#db ,u4,s4,c4 #aciex7 is amended by adding at the end the following new subsection3 7nnn7 ,breakthrough device 7#a7 ,in general ,the term breakthrough device means a device that-- 7,a7 is so designated by the ,secretary under section #ahii;,d2 and 7,b7 is furnished at such frequency as specified in the ,food and ,drug ,administration-approved labeling for such device 7or1 in the case such device has no frequency so specified1 at such frequency as determined appropriate by the ,secretary74 7#b7 ,transitional coverage period ,the term transitional coverage period means1 with respect to a breakthrough device1 the #d-year period that begins on the date that such device is so designated by the ,secretary under section #ahii;,d4 4 7#c7 ,breakthrough device determinations ,part ,e of title ,,xviii of the ,social ,security ,act 7#db ,u4,s4,c4 #aciex et seq47 is amended by adding at the end the following new section3 #ahii;,d4 ,designation of breakthrough devices 7a7 ,in general ,beginning #ah months after the date of the enactment of this section1 upon application of a manufacturer of a device 7as defined in section #bja of the ,federal ,food1 ,drug1 and ,cosmetic ,act7 that is cleared1 classified1 or approved under section #eaj7k71 #eac7;f77#b71 or #eae of such ,act on or after the date of the enactment of this section1 the ,secretary shall designate such device as a breakthrough device if the ,secretary determines that such device meets the criteria specified in subsection 7b74 7b7 ,criteria ,for purposes of subsection 7a71 the criteria specified in this subsection are1 with respect to a device1 the following3 7#a7 ,the device is provided with priority review pursuant to section #eae;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 7#b7 ,in the case such device is cleared under section #eaj7k7 of such ,act1 such device is so cleared based on clinical data1 which may include clinical trial information from an applicable device clinical trial 7as such terms are defined in section #djb7;j7 of such ,act71 that included individuals entitled to benefits under part ,a or enrolled under part ,b4 7#c7 ,the device would1 without application of section #ahfb7;a71 otherwise be covered under part ,a or ,b4 7#d7 ,the device does not1 based on a review of clinical data1 present an undue risk of harm that outweighs the potential clinical benefits for individuals entitled to benefits under part ,a or enrolled under part ,b1 as determined by the ,secretary4 7c7 ,determination process 7#a7 ,in general ,the ,secretary shall make a determination with respect to the designation of a device that is the subject of an application described in subsection 7a7 not later than #f months after such application is submitted to the ,secretary4 7#b7 ,explanation required in case of nondesignation ,with respect to a device that is the subject of an application described in subsection 7a71 in the case that the ,secretary determines that such device does not meet the criteria specified in subsection 7b71 the ,secretary shall notify the manufacturer of such device of such determination and include in such notification an identification of the specific criterion or criteria that such device failed to meet and an explanation of why such device failed to meet such criterion or criteria4 7d7 ,reports ,the ,secretary shall submit to ,congress on an annual basis a report specifying-- 7#a7 the number of applications received under this section during such year2 7#b7 the number of devices designated as breakthrough devices under this section during such year2 and 7#c7 the number of applications for a designation for a device under this section with respect to which the ,secretary determined that such device did not meet the criteria specified in subsection 7b7 during such year4 7e7 ,review of aberrant billing ,the ,secretary may conduct a review of the medical necessity and reasonableness of a breakthrough device furnished by a provider of service or supplier that the ,secretary determines has an aberrant billing pattern with respect to such a device or otherwise is an outlier with respect to the furnishing of such device compared to similarly situated providers of services and suppliers4 4 7b7 ,ensuring issuance of national coverage determination during transition period ,section #ahfb7l77#b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciey7l77#b77 is amended by adding at the end the following new flush sentence3 ,in the case of a request for a national coverage determination with respect to a breakthrough device 7as defined in section #ahfa7nnn771 the ,secretary shall ensure that a final decision is made on such request 7or determine that such device is otherwise covered under this title7 prior to the end of the transitional coverage period 7as so defined7 for such device if such request was submitted to the ,secretary before the date that is #i months 7or #ab months1 in the case such request is a request to which subparagraph 7,b7 applies7 before the last day of such period4 4 7c7 ,funding ,in addition to amounts otherwise available1 there are appropriated to the ,centers for ,medicare ,medicaid ,services ,program ,management ,account1 out of any monies in the ,treasury not otherwise appropriated1 #aj1jjj1jjj for each of fiscal years #bjbe through #bjcj1 to remain available until expended1 to carry out the amendments made by this section4